Leptomycin B Ester Derivatives for Reduced Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving leptomycin compounds as anti-cancer agents suffer from limited structural diversity, low bioconversion yields, and toxicity issues, necessitating an alternative approach to develop more promising compounds with reduced cytotoxicity.
Innovation Solution
Development of compounds with specific structural formulas that include esters of leptomycin B, which inhibit CRM1-mediated nuclear export processes, thereby inhibiting cancer cell proliferation and treating hyperproliferative diseases such as cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LMB is used as an anti-tumor agent, then it exhibits strong anti-tumor activity by inhibiting CRM1-mediated nuclear export, but it shows remarkable cytotoxicity towards mammalian cells leading to extreme toxicity
Solution Approach 1:
The patent applies parameter changes by modifying the ester group at position C4 of the leptomycin B molecule. Different ester groups (methyl, ethyl, propyl, butyl, isopropyl, isobutyl, phenyl, benzyl) are systematically introduced to alter the molecular properties while maintaining the core CRM1-inhibiting structure. This systematic modification allows optimization of the activity-toxicity ratio by changing physical and chemical parameters of the molecule.
Solution Approach 2:
The patent applies local quality by making a specific localized modification at the C4 position of the molecule while leaving the rest of the structure intact. The ester group at C4 is the only variable component, allowing precise control over how the modification affects overall molecular behavior. This localized change preserves the essential pharmacophore while enabling tuning of toxicological properties.
2Quantity of substance
If bioconversion screening with bacteria and fungi is used to derive LMB derivatives, then some derivatives are obtained, but the structural diversity is poor and bioconversion yields are low
Solution Approach 1:
The patent applies copying by using chemical synthesis to replicate and modify the LMB structure directly, rather than relying on biological systems to produce variants. The synthetic approach copies the essential pharmacophore features while systematically introducing desired modifications at the C4 position, ensuring both structural diversity and high yields without the limitations of bioconversion.
Solution Approach 2:
The patent replaces the biological mechanism (bioconversion by bacteria and fungi) with a chemical mechanism (synthetic esterification). This substitution eliminates the inefficiencies of biological systems such as low yields, limited structural diversity, and haphazard modification patterns, while providing controlled, systematic derivation of LMB derivatives.
3Adaptability or versatility
If bioconversion screening is performed to obtain LMB derivatives, then some compounds are isolated, but the positions into which functional groups are introduced are haphazard, precluding systematic derivation of structure-activity relationship
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a fixed core structure (the leptomycin B pharmacophore) and a variable component (the ester group at C4). This segmentation allows systematic exploration of structure-activity relationships by independently varying only the ester group while maintaining precise control over its position. The segmented approach enables methodical derivation of SAR data without the positional randomness inherent in bioconversion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit cancer cell proliferation and induce apoptosis in target cells, offering a more promising anti-cancer approach with reduced toxicity compared to existing leptomycin B derivatives.
Implementation Method 1
LMB acts as an inhibitor of the nuclear export receptor CRM1, which binds to and affects the nuclear translocation of 'cargo proteins' such as P53, P73, STAT1
Data Source
AI summary
Esters of compounds in the leptomycin family, having a structure according to formula Iwhere R, R10, R11, R12, R13, and R14 are as defined herein, exhibit anti-tumor properties.